Syneron Medical

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch ELOS and buy or sell other stocks, ETFs, and their options commission-free!

About ELOS

Syneron Medical Ltd. engages in the development and manufacture of aesthetic products, services, and systems. Its products include Nordlys, Gentle Pro Series, PicoWay, Vbeam Prima, and Profound. 

CEO
Geoffrey Schuyler Crouse, MBA
CEOGeoffrey Schuyler Crouse, MBA
Employees
Employees
Headquarters
Yokneam Illit, HaZafon
HeadquartersYokneam Illit, HaZafon
Founded
2000
Founded2000
Employees
Employees

ELOS Key Statistics

Market cap
385.20M
Market cap385.20M
Price-Earnings ratio
-91.67
Price-Earnings ratio-91.67
Dividend yield
Dividend yield
Average volume
343.68K
Average volume343.68K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$11.43
52 Week high$11.43
52 Week low
$6.18
52 Week low$6.18

Stock Snapshot

As of today, Syneron Medical(ELOS) shares are valued at $11.00. The company's market cap stands at 385.2M, with a P/E ratio of -91.67.

On 2026-08-14, Syneron Medical(ELOS) shares started trading at —, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 343.68K.

Over the past 52 weeks, Syneron Medical(ELOS) stock has traded between a high of $11.43 and a low of $6.18.

Over the past 52 weeks, Syneron Medical(ELOS) stock has traded between a high of $11.43 and a low of $6.18.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.